After decades of incremental progress, at best, in treating advanced prostate cancer, men with androgen independent disease now have many different treatment options. Since 2010, 5 new drugs representing 4 different treatment strategies that offer not only symptom relief, but also longer survival, have been approved by the FDA. Furthermore, stimulated by this success, there is a rich pipeline of drugs representing next, and best in class agents and novel mechanisms jockeying for position in a rapidly evolving treatment paradigm, wherein benchmarks for success continue to rise. This panel will discuss these advancements, and prospects for future efforts, from the perspectives of academic researchers driving the scientific and clinical understanding of prostate cancer and biopharmaceutical industry leaders forming alliances to bring these therapies to patients.
- Jeremy P. Goldberg, President, JPG Healthcare LLC
- Marco Gottardis, Ph D, VP and Prostate Cancer Disease Area Stronghold Leader, Oncology Therapeutic Area, Janssen Research & Development, LLC.
- Richard Heyman, CEO, Seragon (ex-CEO Aragon)
- Philip Kantoff, MD, Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
- Marianne Sadar, PhD, Chief Scientific Officer, ESSA Pharma Inc.
Cancer Progress has an outstanding reputation as the premier annual oncology conference that affords a unique dialogue among 200+ key opinion leaders in the cancer field. Join us as we bring together these top cancer researchers, clinical investigators and senior executives from the pharmaceutical, biotechnology, payer, regulatory and investment arenas. Pivotal topics, frank discussions, vigorous debate, lively audience participation and generous networking combine to make this a highly impactful conference.
The quality of the speaking faculty is a major contributor to the popularity and value of this conference. This year, executives attending the conference will also meet Peter Bach, Anna Barker, Walter Capone, David Curiel, Giulio Draetta, Joel Dudley, Jeffrey Engelman, Jeanne Farrell, David Haslam, Brian Leyland-Jones, Tak Mak, Minesh P. Mehta, H. Ian Robins, Neal Rosen and David Solit, among other prestigious scientists and clinicians.
Our Keynote Speakers
The Song Remains the Same: From Targeted Therapies to a Prerequisite
for Patient Selection
Colin Goddard, PhD, Chairman & Chief Executive Officer, Coferon Incorporated
A Dialogue: Valuing Value in Oncology
Professor David Haslam, CBE, FRCGO, FRCP, FFPH, Chairman, NICE
Peter Bach, MD, Attending Physician, Memorial Sloan-Kettering Cancer Center
Clifford A. Hudis MD, Chief, Breast Cancer Medicine Service, Memorial Sloan-Kettering